Annovis Bio Showcases its Unique Approach to Alzheimer's at the New York Academy of SciencesGlobeNewsWire • 12/15/20
Annovis Bio to Present at the New York Academy of Sciences' Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual ConferenceGlobeNewsWire • 12/03/20
Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer's and Parkinson's DiseasesGlobeNewsWire • 11/12/20
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease after COVID-Related DelayGlobeNewsWire • 10/29/20
Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times' Outstanding Directors Exchange and Panel Discussion at the Angel Venture FairGlobeNewsWire • 10/20/20
Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s DiseaseGlobeNewsWire • 09/29/20
Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s TrialGlobeNewsWire • 09/01/20
Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s DiseasesGlobeNewsWire • 08/20/20
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of PennsylvaniaGlobeNewsWire • 07/20/20
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s PatientsGlobeNewsWire • 07/07/20
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology StudyGlobeNewsWire • 06/16/20
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401GlobeNewsWire • 06/02/20
Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19GlobeNewsWire • 05/27/20
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s PatientsGlobeNewsWire • 04/30/20
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology StudiesGlobeNewsWire • 02/27/20
Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body DiseasesGlobeNewsWire • 02/20/20